Data Analysis suggesting a Correlation between Positive Covid-19 and decreased in Cognitive Performance

Alzheimer's is a neurological disease that can affect the population as early as 40-50 years old until 90-100 years old. Some of the symptoms include confusion, difficulty remembering familiar concepts, making decisions, and memory loss. The main biological cause for the development of this disease is the accumulation of amyloid plaques (composed of amyloid-beta peptides) found in the brain. Although there is no specific causation, it is apparent that many environmental, genetic, and biological factors play a role in the development of this disease. LEADS is a Longitudinal Early-Onset Observational study of Alzheimer's, enrolling adults from 40-64 years old and collecting their genetic, biological, and cognitive background. Recent studies have reported increasing data indicating a correlation between COVID-19 and suffering from further cognitive impairment. Utilizing COVID-19 NACC (National Alzheimer’s Coordinating Center) survey given to LEADS subjects and MoCA (Montreal Cognitive Assessment) results, data analysis will be performed to confirm a correlation of COVID-19 and a cognitive decline. The collection of MoCA results will attempt to parallel the subject's timeline pre-COVID and post-COVID.